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   A new radioimmunoassay kit （GammaDab PAP kit） was evaluated． Result of precision and
accuracy tests was satisfactory． ln the clinical phase， serum PAP level was measured in the serum
obtained from 22 patients with treated and untreated prostatic cancer， 20 patients with benign pro－
static hyperplasia， 20 patients with other urological diseases， 114 patients with other nonurological
diseases and 45 volunteers of healthy males and females．
   Normal serum PAP levels of healthy m41es Seem to be O．85±O．285 ng／ml in our assay． In 7 cases
of advanced prostatic cancer（32％＞seru皿PAP Ievel was elevated ovcr 5．O ng／ml and nonprost’atic
cancer did not exceed this level． From this result， it may ． be conclUded th4t if setum PAP level is
higheir than 5．0 ng／ml， prostatic cancer at least advanced is strongly suspected， and its prognostic
usefulness in prostatic cancer may be expected．
   As conclusion the method of radioimmunoassay for rneasurement of PAP is much more reliable



















 前立腺癌未治療8例（Stage C 1例， Stage D 6例，
不明1例）






















   工は2±0・6ng／ml，」は12土2．4 ng／mlを含む
 E．PAPブランク血清
 F．PAP標準血清（BPH患者に由来する）
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Table 2． lriter－assay variance
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Fig． 2，，Effect of incubation temperature on



























































Fig． 3． Dilution test
Table 3． Recovery test
1
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Fig． 4． Serum PAP levels in healthy males and females．
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Fig． 7． Distribution of serum PAP levels in patients with prostatic
















             Table 4．
泌尿紀要 27巻111号 1981年









とうりである．M－o．78 ng／m1， s．D，一〇．285 ng／ml，
M十3s．D．＝1．64 ng／m1と測定された．
 iii）年齢別変化
 Fig。5は男子， Fig． 6は女子における全測定値（除
前立腺疾患）を示し・たもので，加齢による変化はみら
Serum PAP levels in various diseases
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 3）GOT， GPT高値群のPAP値． Fig．8でGPT
が比較的高値の20例のPAPとGPT値との関係を示
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 健康男子ではM＝0・86 ngfml， S・D・＝0・285 ng／m1，
M十3 S．D．＝1．72 ng／mlとなる．この値は藤井らが栄
研PAP kitを使用しM十3s．D．＝4．25 ng／m18），鴛























































Stage I 33％，■79％，皿 71％， IV 92％の診断率と
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